global
Variables
Utilities
CUSTOM STYLES

FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression

May 19, 2020

On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having high expressions of PD-L1 (>50%) and no changes in EGFR or ALK. The FDA based their approval on the results of the clinical trial IMpower-110 which showed that patients receiving Tecentriq (atezolizumab) lived longer, had a higher chance of responding well to treatment, and went longer periods of time without progression than those receiving chemotherapy.Tecentriq (atezolizumab) being available as a first line immunotherapy option for NSCLC gives patients more options for first line treatments than ever before.Click here to read the full press release.

This is some text inside of a div block.

Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.